A new trading day began on Tuesday, with Aquestive Therapeutics Inc (NASDAQ: AQST) stock price up 6.94% from the previous day of trading, before settling in for the closing price of $3.60. AQST’s price has ranged from $1.84 to $6.23 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -4.81% over the last five years. Meanwhile, its annual earnings per share averaged -235.90%. With a float of $77.61 million, this company’s outstanding shares have now reached $91.18 million.
The firm has a total of 135 workers. Let’s measure their productivity. In terms of profitability, gross margin is 69.39%, operating margin of -35.83%, and the pretax margin is -59.58%.
Aquestive Therapeutics Inc (AQST) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Aquestive Therapeutics Inc is 14.88%, while institutional ownership is 45.89%. The most recent insider transaction that took place on Nov 26 ’24, was worth 214. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $4.87, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 15 ’24, when Company’s Chief Innovation/Tech Officer sold 50,000 for $6.00, making the entire transaction worth $300,000. This insider now owns 984,476 shares in total.
Aquestive Therapeutics Inc (AQST) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -235.90% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Here are Aquestive Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Analysing the last 5-days average volume posted by the [Aquestive Therapeutics Inc, AQST], we can find that recorded value of 1.53 million was lower than the volume posted last year of 1.74 million. As of the previous 9 days, the stock’s Stochastic %D was 12.64%. Additionally, its Average True Range was 0.27.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 29.86%, which indicates a significant increase from 16.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.54% in the past 14 days, which was lower than the 69.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.78, while its 200-day Moving Average is $4.05. Now, the first resistance to watch is $3.94. This is followed by the second major resistance level at $4.04. The third major resistance level sits at $4.16. If the price goes on to break the first support level at $3.73, it is likely to go to the next support level at $3.61. Now, if the price goes above the second support level, the third support stands at $3.51.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
With a market capitalization of 351.04 million, the company has a total of 91,178K Shares Outstanding. Currently, annual sales are 50,580 K while annual income is -7,870 K. The company’s previous quarter sales were 13,540 K while its latest quarter income was -11,510 K.
